Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000410134 | SCV000485546 | likely pathogenic | PMM2-congenital disorder of glycosylation | 2015-12-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000410134 | SCV000956936 | pathogenic | PMM2-congenital disorder of glycosylation | 2022-11-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Studies have shown that disruption of this splice site results in skipping of exons 3 and 4 and introduces a premature termination codon (PMID: 19235233). The resulting mRNA is expected to undergo nonsense-mediated decay. ClinVar contains an entry for this variant (Variation ID: 370282). Disruption of this splice site has been observed in individual(s) with congenital disorder of glycosylation type 1a (PMID: 19235233). This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change affects an acceptor splice site in intron 3 of the PMM2 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. |
Centre for Mendelian Genomics, |
RCV000410134 | SCV001369687 | pathogenic | PMM2-congenital disorder of glycosylation | 2019-12-13 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS2,PM2,PP5. |
Fulgent Genetics, |
RCV000410134 | SCV002794920 | likely pathogenic | PMM2-congenital disorder of glycosylation | 2022-03-23 | criteria provided, single submitter | clinical testing |